ESMO TAT 2022 | Potential of molecular imaging be used as a biomarker in cancer care

David Mankoff, MD, PhD, University of Pennsylvania, Philadelphia, PA, discusses the current landscape of molecular imaging for the prediction and assessment of responses to cancer therapeutics, and the potential for it to be used as a biomarker that can guide treatment decisions, not just as a tool for diagnosis and staging of cancers. Dr Mankoff also explains how radionucleotide theranostics work. This interview was conducted at the virtual European Society for Medical Oncology Targeted Anti-Cancer Therapies (ESMO TAT) Congress 2022.